Clinical Edge Journal Scan

PsA: Clinical and therapeutic features associated with early vs late onset of psoriasis


 

Key clinical point: In patients with psoriatic arthritis (PsA), early onset psoriasis (EOP) was linked to dactylitis and more frequent use of anti-interleukin 17 (anti-IL17) drugs, whereas late onset psoriasis (LOP) was associated with a higher use of nonsteroidal anti-inflammatory drugs (NSAID) and conventional synthetic disease-modifying antirheumatic drugs (csDMARD).

Major finding: Patients in the EOP vs LOP group had a 9 times higher probability of dactylitis (odds ratio [OR] 9.64; P < .001) and reported a higher use of anti-IL17 drugs (26.8% vs 13.5%; P = .039); meanwhile, in the LOP vs EOP group, the use of NSAID (29.7% vs 12.2%; P = .016) and csDMARD (21.6% vs 7.3%; P < .01) was more frequent.

Study details: The data come from a cross-sectional analysis of a longitudinal cohort including 160 patients with PsA, of which 84 had EOP (0-40 years) and 76 patients had LOP (>40 years).

Disclosures: This study did not receive any funding or sponsorship. The authors declared no conflicts of interest.

Source: Scriffignano S et al. Dactylitis and early onset psoriasis in psoriatic arthritis: Are they markers of disease severity? A clinical study. Rheumatol Ther. 2022 (Jun 17). Doi: 10.1007/s40744-022-00468-3

Recommended Reading

Methotrexate’s impact on COVID-19 vaccination: New insights made
MDedge Rheumatology
NAFLD strongly correlated with psoriasis, PsA; risk linked to severity
MDedge Rheumatology
Questionnaire for patients with psoriasis might identify risk of axial involvement
MDedge Rheumatology
Rapid and sustained improvement in diverse PsA manifestations with guselkumab
MDedge Rheumatology
PsA: Long-term efficacy and safety of ixekizumab with or without csDMARD
MDedge Rheumatology
PsA: Sustained improvement in patient-reported outcomes with bimekizumab
MDedge Rheumatology
PsA: Risankizumab improves patient-reported outcomes in phase 3 trial
MDedge Rheumatology
Guselkumab leads to meaningful and consistent improvement in general health outcomes in PsA
MDedge Rheumatology
PsA: Long-term retention, efficacy, and safety of secukinumab in real world
MDedge Rheumatology
Reluctance of biologic initiation in systemic-therapy-naive PsA patients receiving apremilast
MDedge Rheumatology